Nerve growth factor: An update on the science and therapy

Osteoarthritis and Cartilage

Volumn 21, Issue 9, 2013, Pages 1223-1228

  Seidel, M F ^a   Wise, B L ^b   Lane, N E ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Nerve growth factor; Neurogenic inflammation; Osteoarthitis; Receptor antagonists

Indexed keywords

CELECOXIB; DICLOFENAC; FULRANUMAB; NAPROXEN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; OXYCODONE; PARACETAMOL; TANEZUMAB; TRAMADOL;

ABNORMAL SENSATION; ANALGESIC ACTIVITY; ARTHRALGIA; BACKACHE; CHRONIC PAIN; DIARRHEA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG SAFETY; HIP OSTEOARTHRITIS; HUMAN; HYPERESTHESIA; HYPESTHESIA; JOINT PROSTHESIS; KNEE OSTEOARTHRITIS; KNEE PAIN; LOW BACK PAIN; MYALGIA; NEUROGENIC INFLAMMATION; NOCICEPTION; NOCICEPTIVE PAIN; NONHUMAN; OSTEOARTHRITIS; PAIN ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE;

NERVE GROWTH FACTOR; NEUROGENIC INFLAMMATION; OSTEOARTHITIS; RECEPTOR ANTAGONISTS;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BACK PAIN; HUMANS; NERVE GROWTH FACTOR; NEURITIS; OSTEOARTHRITIS;

EID: 84882667218     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2013.06.004     Document Type: Review

References (47)

1. Seidel M., Tsalik J., Vetter H., Müller W. Substance P in rheumatic diseases. Curr Rheum Rev 2007, 3:17-30.
2. Ferrell W.R., Russell N.J. Extravasation in the knee induced by antidromic stimulation of articular C fibre afferents of the anaesthetized cat. JPhysiol 1986, 379:407-416.
3. Levine J.D., Clark R., Devor M., Helms C., Moskowitz M.A., Basbaum A.I. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984, 226(4674):547-549.
4. Lindsay R.M., Harmer A.J. Nerve growth factor regulates expression of neuropeptides genes in adult sensory neurons. Nature 1989, 337:362-364.
5. Leibrock J., Lottspeich F., Hohn A., Hofer M., Hengerer B., Masiakowski P., et al. Molecular cloning and expression of brain-derived neurotrophic factor. Nature 1989, 341(6238):149-152.
6. Ernfors P., Ibáñez C.F., Ebendal T., Olson L., Persson H. Molecular cloning and neurotrophic activities of a protein with structural similarity to nerve growth factor: developmental and topographical expression in the brain. Proc Natl Acad Sci USA 1990, 87(14):5454-5458.
7. Maisonpierre P.C., Belluscio L., Squinto S., Ip N.Y., Furth M.E., Lindsay R.M., et al. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 1990, 247(4949):1446-1451.
8. Hallbook F., Ibanez C.F., Persson H. Evolutionary studies of nerve growth factor family reveal a new member abundantly expressed in Xenopus ovary. Neuron 1991, 6:845-858.
9. Berkemeier L.R., Winslow J.W., Kaplan D.R., Nikolics K., Goeddel D.V., Rosenthal A. Neurotrophin-5: a novel neurotrophic factor that activates trk and trkB. Neuron 1991, 7(5):857-866.
10. Kojima M., Ikeuchi T., Hatanaka H. Role of nerve growth factor in the expression of trkA mRNA in cultured embryonic rat basal forebrain cholinergic neurons. JNeurosci Res 1995, 42(6):775-783.
11. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 2001, 24:1217-1281.
12. Gee A.P., Boyle M.D., Munger K.L., Lawman M.J., Young M. Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis invitro. Proc Natl Acad Sci USA 1983, 80(23):7215-7218.
13. Otten U., Baumann J.B., Girard J. Nerve growth factor induces plasma extravasation in rat skin. Eur J Pharmacol 1984, 106(1):199-201.
14. Lewin G.R., Ritter A.M., Mendell L.M. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. JNeurosci 1993, 13(5):2136-2148.
15. Petty B.G., Cornblath D.R., Adornato B.T., Chaudhry V., Flexner C., Wachsman M., et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994, 36:244-246.
16. Garner B.C., Stoker A.M., Kuroki K., Evans R., Cook C.R., Cook J.L. Using animal models in osteoarthritis biomarker research. JKnee Surg 2011, 24(4):251-264.
17. Seidel M.F., Herguijuela M., Forkert R., Otten U. Nerve growth factor in rheumatic diseases. Semin Arthritis Rheum 2009, 40(2):109-126.
18. Obata K., Tsujino H., Yamanaka H., Yi D., Fukuoka T., Hashimoto N., et al. Expression of neurotrophic factors in the dorsal root ganglion in a rat model of lumbar disc herniation. Pain 2002, 99(1-2):121-132.
19. Bileviciute I., Lundeberg T., Ekblom A., Theodorsson E. Bilateral changes of substance P-, neurokinin A-, calcitonin gene-related peptide- and neuropeptide Y-like immunoreactivity in rat knee joint synovial fluid during acute monoarthritis. Neurosci Lett 1993, 153(1):37-40.
20. Garry M.G., Hargreaves K.M. Enhanced release of immunoreactive CGRP and substance P from spinal dorsal horn slices occurs during carrageenan inflammation. Brain Res 1992, 582(1):139-142.
21. Kuraishi Y., Nanayama T., Ohno H., Fujii N., Otaka A., Yajima H., et al. Calcitonin gene-related peptide increases in the dorsal root ganglia of adjuvant arthritic rat. Peptides 1989, 10(2):447-452.
22. Isola M., Ferrari V., Miolo A., Stabile F., Bernardini D., Carnier P., et al. Nerve growth factor concentrations in the synovial fluid from healthy dogs and dogs with secondary osteoarthritis. Vet Comp Orthop Traumatol 2011, 24(4):279-284.
23. Lewin G.R., Rueff A., Mendell L.M. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 1994, 6(12):1903-1912.
24. McMahon S.B., Bennett D.L.H., Priestly J.V., Shelton D.L. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by trkA-IgG fusion molecule. Nat Med 1995, 1(8):774-780.
25. Woolf C.J., Safieh-Garabedian B., Ma Q.P., Crilly P., Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience 1994, 62(2):327-331.
26. Theodosiou M., Rush R.A., Zhou X.F., Hu D., Walker J.S., Tracey D.J. Hyperalgesia due to nerve damage: role of nerve growth factor. Pain 1999, 81(3):245-255.
27. Owolabi J.B., Rizkalla G., Tehim A., Ross G.M., Riopelle R.J., Kamboj R., et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. JPharmacol Exp Ther 1999, 289(3):1271-1276.
28. Koewler N.J., Freeman K.T., Buus R.J., Herrera M.B., Jimenez-Andrade J.M., Ghilardi J.R., et al. Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. JBone Miner Res 2007, 22(11):1732-1742.
29. Ugolini G., Marinelli S., Covaceuszach S., Cattaneo A., Pavone F. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc Natl Acad Sci USA 2007, 104(8):2985-2990.
30. McNamee K.E., Burleigh A., Gompels L.L., Feldmann M., Allen S.J., Williams R.O., et al. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. Pain 2010, 149(2):386-392.
31. Dawbarn D., Fahey M., Watson J., Tyler S., Shoemark D., Sessions R., et al. NGF receptor TrkAd5: therapeutic agent and drug design target. Biochem Soc Trans 2006, 34(Pt 4):587-590.
32. Katz N., Borenstein D.G., Birbara C., Bramson C., Nemeth M.A., Smith M.D., et al. Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain 2011, 152(10):2248-2258.
33. Kivitz A., Gimbel J., Bramson C., Nemeth M.A., Keller D., Brown M.T., et al. Astudy of tanezumab in adults with chronic low back pain (NCT00876187). Arthritis Rheum 2011, 63(S10):S288-S289. (Abstract).
34. Sanga P., Karcher K., Wang S., Kelly K., Oh C., Thipphawong J. Efficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe, chronic low back pain. JPain 2011, 12(S4):53. (Abstract).
35. Lane N.E., Schnitzer T.J., Birbara C.A., Mokhtarani M., Shelton D.L., Smith M.D., et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. NEngl J Med 2010, 363(16):1521-1531.
36. Schnitzer T.J., Lane N.E., Birbara C., Smith M.D., Simpson S.L., Brown M.T. Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage 2011, 19(6):639-646.
37. Brown M.T., Murphy F.T., Radin D.M., Davignon I., Smith M.D., West C.R. Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. JPain 2012, 13(8):790-798.
38. Nagashima H., Suzuki M., Araki S., Yamabe T., Muto C. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage 2011, 19(12):1405-1412.
39. Fidelholtz J., Tark M., Spierings E., Wolfram G., Annis K., Smith M.D., et al. Aphase 3 placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis. Arthritis Rheum 2011, 63(Suppl 10):S427. (Abstract).
40. Feist E., Balanescu A., Wolfram G., Davignon I., Smith M.D., Brown M.T., et al. Efficacy and safety of tanezumab added on to diclofenac in patients with knee or hip osteoarthritis (NCT00864097). Arthritis Rheum 2011, 63(Suppl 10):S427-S428. (Abstract).
41. Yazici Y., Ekman E.F., Greenberg H.S., Smith M.D., Brown M.T., West C.R., et al. Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354). Arthritis Rheum 2011, 63(Suppl 10):S326. (Abstract).
42. Postel M., Kerboull M. Total prosthetic replacement in rapidly destructive arthrosis of the hip joint. Clin Orthop Relat Res 1970, 72:138-144.
43. Bello A.E., Ekman E.F., Radin D.M., Davignon I., Smith M.D., Brown M.T., et al. Long-term tanezumab treatment for osteoarthritis: efficacy and safety results. Arthritis Rheum 2012, 64(Suppl 10):S112. (Abstract).
44. Sanga P., Katz N., Polverejan E., Wang S., Kelly K., Oh C., et al. Efficacy, safety, and tolerability of fulranumab, an antinerve growth factor antibody, in treatment of patients with moderate-to-severe osteoarthritis pain. Pain 2011, 12(Suppl 4):53. (Abstract).
45. Hochberg M.C., Abramson S.B., Hungerford D.S., McCarthy E., Vignon E.P., Smith M.D., et al. Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheum 2012, 64(Suppl 10):S113. (Abstract).
46. Ehrlich G.E. Erosive osteoarthritis: presentation, clinical pearls, and therapy. Curr Rheumatol Rep 2001, 3(6):484-488.
47. Seidel M.F., Lane N.E. Control of arthritis pain with anti-nerve-growth factor: risk and benefit. Curr Rheumatol Rep 2012, 14(6):583-588.